Key Drivers
- Margin Recovery
- Heavy Leverage
- Positive FCF
AIAI Summary
BLCO now looks like a credible operational turnaround—revenue, margins, and free cash flow are improving—but until it meaningfully reduces leverage and clears the governance overhang, the stock remains a “prove it” story rather than a clean rerating candidate.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Recovery
- •Heavy Leverage
- •Positive FCF
BLCO's latest quarter shows meaningful margin and cash-flow improvement, but the company still faces heavy leverage and weak interest coverage despite trading below book value.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Mid-16s support
- •Range resistance
BLCO has shown a mild improving uptrend over the last month, holding higher lows and staying constructive above the mid-$16s, but it still needs a clean break above $17.10-$17.16 to confirm further upside.
Sharp drop on 2026-08-06 briefly broke the rebound and added volatility
Sentiment & News
Key News Insights:
- •Revenue acceleration
- •Guidance raised
- •Product rollout
Bausch + Lomb is showing improving momentum as Q2 growth, raised guidance, and active product launches outweigh a routine insider sale.
The news is modestly positive for BLCO, signaling stronger operating execution and a better near-term earnings outlook
Similar Companies in Healthcare
Other companies in the same sector with AI ratings